Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 May;26(5):481-9.
doi: 10.1007/BF03345206.

Testosterone replacement therapy in male hypogonadism

Affiliations
Review

Testosterone replacement therapy in male hypogonadism

M Byrne et al. J Endocrinol Invest. 2003 May.

Abstract

In human males 6-7 mg of testosterone are secreted by the testes in a circadian rhythm with a nocturnal rise in testosterone followed by a decline during the day. Testosterone is necessary to induce and maintain secondary sexual characteristics, lean muscle mass, bone density and for normal sexual behaviour and cognitive function in men. Replacement therapy has been shown to be beneficial in men with overt hypogonadism. Natural testosterone should be used and not modified molecules. Testosterone is currently available in oral, intramuscular, subcutaneous and transdermal preparations. Recent advances in testosterone replacement therapy include testosterone gels which provide flexibility in dosing and minimal skin irritation resulting in good compliance, and the development of longer acting intramuscular preparations which result in more stable testosterone levels with longer injection intervals. All patients receiving testosterone should be carefully monitored for changes in hematocrit, liver function, lipid parameters and prostate specific antigen (PSA).This article reviews the current experience with the use of various forms of testosterone for the treatment of male hypogonadism.

PubMed Disclaimer

References

    1. J Clin Endocrinol Metab. 1999 Jun;84(6):1966-72 - PubMed
    1. J Androl. 2002 May-Jun;23(3):419-25 - PubMed
    1. Lancet. 2002 Jan 5;359(9300):44-6 - PubMed
    1. N Engl J Med. 1983 Mar 3;308(9):508-10 - PubMed
    1. J Clin Endocrinol Metab. 2001 Nov;86(11):5547-53 - PubMed

LinkOut - more resources